Lipocine Inc (LPCN) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $25. H.C. Wainwright advised their investors in a research report released on Oct 7, 2016.
Lipocine Inc closed down -0.29 points or -6.39% at $4.25 with 1,58,117 shares getting traded on Tuesday. Post opening the session at $4.56, the shares hit an intraday low of $4.22 and an intraday high of $4.56 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Oct 2, 2015, John W. Higuchi (director) purchased 5,000 shares at $12.68 per share price. According to the SEC, on Oct 2, 2015, Mahesh V. Patel (CEO) purchased 4,000 shares at $11.78 per share price.
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company’s primary development programs are based on oral delivery solutions for bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements bypass first-pass metabolism reduce side effects and eliminate gastrointestinal interactions that limit bioavailability. The Company’s lead product candidate LPCN 1021 is an oral testosterone replacement therapy (TRT) designed for twice-a-day dosing and is in Phase III testing. Additional pipeline candidates include LPCN 1111 an oral testosterone therapy product targeted for once daily dosing which is in Phase II testing and LPCN 1107 an oral therapy for the prevention of preterm birth which is in Phase I testing.